Cover Image
Market Research Report

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 229718
Published Content info 2062 Pages
Delivery time: 1-2 business days
Price
Back to Top
Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019
Published: December 16, 2019 Content info: 2062 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 103, 107, 1, 11, 159, 29 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 13, 18, 5, 31 and 8 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11694IDB

Table of Contents

  • Introduction
  • Multiple Myeloma (Kahler Disease) - Overview
  • Multiple Myeloma (Kahler Disease) - Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aevi Genomic Medicine Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Altor Bioscience LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ascenta Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ascentage Pharma Group International, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Asclepius Technology Company Group Suzhou Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Auransa Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Therapeutics Plc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bantam Pharmaceutical LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by BioLineRx Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biosion Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by BioVec Pharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by BiVictriX Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boryung ViGenCell Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CARsgen Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cartesian Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CASI Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CellCentric Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellestia Biotech AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cello Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celularity Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Centrax International Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Checkpoint Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by ChemioCare USA Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chipscreen Biosciences Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CiMaas BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CRISPR Therapeutics AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curocell Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyteir Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cytonus Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by DeuteRx LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Diverse Biotech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by EpicentRx Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Epizyme Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by EUSA Pharma (UK) Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by ExCellThera Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Fate Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Fera Pharmaceuticals LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Fortis Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gadeta BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Galileo Research srl, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GEMoaB Monoclonals GmbH, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GemoPharm, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genentech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genmab A/S, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gilead Sciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Glycostem Therapeutics BV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gracell Bio, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by GT Biopharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by HaemaLogix Pty Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Harbour BioMed, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Harpoon Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Helix BioPharma Corp, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Helocyte Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hengenix Biotech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hillstream BioPharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hinova Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by HitGen LTD, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by HRAIN Biotechnology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by HuniLife Biotechnology Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by iCell Gene Therapeutics LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Iceni Pharmaceuticals Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ichnos Sciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by IDAC Theranostics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by IDP Discovery Pharma SL, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGM Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by ImmuneTarget Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunotech Biopharm Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incuron LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Indapta Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inmune Bio Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Innovative Cellular Therapeutics Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Intra-Immusg Pvt Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inven2 AS, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by IO Biotech ApS, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ionova Life Science Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Istesso Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Iterion Therapeutics, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Janpix Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by JN Biosciences LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by JSK Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jubilant Biosys Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Juno Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Juventas Cell Therapy Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kangpu Biopharmaceuticals Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kiadis Pharma NV, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kleo Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Komipharm International Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kymab Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Les Laboratoires Servier SAS, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Leukogene Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ligand Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Lokon Pharma AB, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Luye Pharma Group Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Machavert Pharmaceuticals LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Marker Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Max Biopharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by MedPacto Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck KGaA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Modulation Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing CART Medical Technology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Legend Biotech Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nektar Therapeutics, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by NexImmune Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Northlake International LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncoceutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoFusion Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncology Venture A/S, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoTherapy Science Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by One World Cannabis Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Peptron Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Anke Cellular Therapeutics Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Biomedicine Suzhou Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Phosplatin Therapeutics LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by PI Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pimera Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Poseida Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Precision Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quadriga BioSciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Qwixel Therapeutics LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rainier Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rapa Therapeutics LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Samus Therapeutics LLC, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selenity Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by SELLAS Life Sciences Group Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Bioray Laboratory Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Theorion Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shenogen Pharma Group Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by SignalRx Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by SignPath Pharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Triumvira Immunologics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Unum Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H2 2019
  • Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H2 2019
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2019
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top